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1 Introduction 
__________________________________________________ 
1.1 Anti-glomerular basement membrane disease 
1.1.1 History 
Anti-GBM (Anti-glomerular basement membrane) disease is an autoimmune disease 
presenting as small vessel vasculitis that affects kidney glomerular as well as pulmonary 
capillaries [1], [2]. In 1958, Stanton et al. published a case series of patients suffering from 
lung hemorrhage and glomerulonephritis and first used the term "Goodpasture's syndrome" 
in honor of Ernest Goodpasture, who published the first case report already in 1919 [3]–[5]. 
With the introduction of immunofluorescence techniques, a characteristic GBM deposition 
of antibodies in a linear fashion was found [6], [7]. Anti-GBM disease manifests in the 
kidneys and lungs because the antibodies bind to a specific basement membrane antigen 
shown to be the non-collagenous domain of the alpha 3 chain (Collagen, type IV)[8]–[11]. 
Anti-GBM disease, which only impacts the kidneys, is known as anti-GBM glomerulonephritis. 
In addition, rapidly progressive type 1 glomerulonephritis, Goodpasture disease and anti-
GBM nephritis point to the same type of disease, though they have different definitions [12]. 
The term "Goodpasture disease" was first used in 1958 by Tange [4] and is used to refer to 
patients with anti-GBM antibodies. The co-presentation of anti-GBM and pulmonary 
hemorrhage from any cause is referred to as "Goodpasture syndrome" whereas "anti-GBM 
disease" includes a wider range of kidney and lung diseases [1], [13], [14]. The general 
disease blueprint is shown in Figure 1. 
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Figure 1  Schematic of the pathogenic mechanisms involved in anti-GBM disease 
Anatomy of the longitudinal section of the kidneys, showing the medulla, cortex, vein, and artery (a). Magnified 
glomerulus, the main filtration unit of the kidney (b). Detailed ultrastructure of the glomerular basement 
membrane (c). Antibodies in the serum pass through the endothelium and bind to the GBM membrane; 
antibody deposition in the GBM causes inflammation and injury thereby initiating and promoting disease 
progression. 
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1.1.2 Epidemiology 
The incidence and prevalence of anti-GBM diseases in the population are limited [15], 
[16]. Although there are no definite epidemiological data on the incidence of the disease, it 
is estimated to be less than one case per million per year [15]. The incidence rates in Europe 
and Asia are higher than in African, supporting a genetic susceptibility to the disease [1], [15], 
[17]. Some studies indicate that disease outbreaks and epidemics are seasonal, so 
environmental factors may play a role, especially influenza A, for which an association with 
the development of anti-GBM disease has been shown [8], [18]–[22]. 
Resistance to anti-GBM disease has been shown to be closely related to certain 
genetic factors. Despite limited big data-related epidemiological studies, genetic analyses 
have confirmed this relationship; for example, anti-GBM disease susceptibility is related to 
the Fc gamma receptors [22]–[24]. The association between human HLA (leukocyte antigen) 
and anti-GBM disease is better defined, as the HLA-DR2 haplotype is found in almost 80% of 
patients [25]. A hierarchy of associations has been recognized by genotyping studies with 
specific DRB1 alleles, revealing the protective effects of the DRB1*01 allele and the 
susceptibility associated with the DRB1*03 and DRB1*04 alleles [21], [22]. These alleles are 
common in the general population and are related to many other autoimmune diseases 
including Sjogren syndrome, explaining why genotyping is not usually performed in clinical 
practice. Anti-GBM disease is one cause of the clinical entity “rapidly progressive 
glomerulonephritis”. Anti-GBM antibodies and the classical histologic presentation of anti-
GBM disease are detected in almost 10%-15% of patients who have rapidly progressive 
glomerulonephritis; again, the percentages vary between different populations [26], [27]. 
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1.1.3 Diagnosis 
AKI (Acute kidney injury) is characterized by a rapid kidney function loss and an 
increase in serum creatinine concentration, mainly due to a decrease in the glomerular 
filtration rate [28]. In the case of AKI, early serological detection of anti-GBM antibodies can 
guide the onset of treatment and improve patient outcomes [29]. Many clinicians 
increasingly rely on this test to affirm the diagnosis and some believe that kidney biopsy has 
possibly become obsolete for establishing the diagnosis [30]. There are certain shortcomings 
in this strategy, firstly, in anti-GBM disease the amount of histological injury rather than the 
titer of autoantibodies determines kidney recovery and hence prognosis, as well as the 
likelihood of recurrence [30]. Secondly, in polyclonal activation states, for example, HIV 
infection and multiple kidney pathologies, false positive detection of anti-GBM antibodies 
may occur [30]. Ultimately, diagnosis may be postponed until a renal biopsy is performed in 
rare patients who have no circulating anti-GBM antibodies [30]. The diagnosis of serologic 
diseases is based upon enzyme-related immunosorbent assays that are now standard 
antibody detection methods. The specificity and sensitivity of such assays is high, ranging 
from 90% to 100% and 94.7% to 100%, respectively [31]. 
1.1.4 Treatment 
Considering that the main pathogenic mechanism of anti-GBM disease is antibody-
specific binding to the basement membrane, rapid removal of antibodies from the blood by 
plasma exchange is the main treatment method for this disease [1]. Other treatment options 
used in clinical practice include corticosteroids and cyclophosphamide [1]. The main 
therapeutic principles are to ameliorate end-organ inflammation and inhibit autoantibody 
production, respectively [1] [32]. Often, doctors do not treat patients with one method 
exclusively, but use a combination of two methods with complementary functions to 
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optimize treat outcomes [32]. For example, plasma exchange combined with 
immunosuppressants improves renal function and survival compared with the use of 
immunosuppressants alone [8]. Patients with moderate renal impairment experienced 
significant recovery after treatment with plasma exchange and immunosuppression, but 
patients with severe renal failure experienced limited therapeutic benefit [8], [27], [33]. In 
one study, 19 patients with anti-GBM disease received plasma exchange, prednisolone and 
cyclophosphamide. The data demonstrated that patients who have a creatinine 
concentration of less than 500 µmol/L showed “100% patient survival and 95% renal survival 
at 1 year and 84% patient survival and 74% renal survival at last follow-up (median 90 
months)” [8]. Therefore, patients who have severe renal function failure should be treated 
with plasma exchange combined with immunosuppressive agents as soon as possible to 
restore the renal function of patients early in the disease; the possibility of renal recovery in 
patients requiring immediate dialysis is almost zero. 
1.1.5 Mouse model of anti-GBM nephritis 
The anti-GBM mouse model was established in 1932 by Masugi et al. [34]. It should be 
noted that the mouse model can acutely be established both by a single large dose of 
antibodies causing to crescent GN (known as the “heterologous model”) or by repetitive 
small doses of anti-GBM antibodies sub-acutely causing to immune complex GN(known as 
the “autologous mode) [35]. In addition, the dose of antibody administered, animal species 
used for the model, as well as the intensity of the host's immune response, all affect the 
severity of the model. For example, chronic glomerulonephritis frequently develops in the 
rat during the heterologous phase showing predominantly exudative lesions [34]. The 
heterologous model was used in our experiments as it causes actual anti-GBM disease rather 
than immune-complex disease observed using the autologous model. 
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 In this research, 24 hours and 7 days time-points were used. Serum and urine were 
collected on days ˗1, 0, 1 and 7. Anti-GBM serum or phosphate-buffered saline  were 
injected on day 0, and mice were euthanized on days 1 and 7. The disease pathology is 
expected to peak around days 1 or 2 after serum injection, then slowly recover [36]. 
1.1.6 Molecular mechanisms of anti-GBM disease 
It is well-established that nephritis can cause AKI. Although anti-GBM nephritis is a 
rare disease, it can cause kidney damage at a rapid rate and lead to end stage renal disease 
within weeks of onset. This is because anti-GBM antibodies can rapidly bind to the basement 
membrane, thereby activating the complement system of the immune system, and 
glomerular basement membrane endothelial cells and podocytes are subsequently damaged 
and vascular permeability is increased, causing albuminuria as well as hematuria as clinical 
manifestations of AKI. Although not fully elucidated, the mechanisms involved include 
podocyte loss [37][38], increased vascular permeability [39][40] and inflammation [41].  
Thus, to tackle this problem, we need to explore molecular mechanisms that can 
prevent the production of antibody or antibody binding and further aggravate kidney 
damage. More basic research on the mechanism of the disease needs to be done to 
ultimately achieve better treatment outcomes for anti-GBM nephritis.  
1.2 Carcinoembryonic antigen-related cell adhesion molecule 1 
biology 
1.2.1 CEACAM1 
CEACAM1 (Carcinoembryonic antigen-related cell adhesion molecule 1), also called 
CD66a, is a highly glycosylated cellular adhesion molecule and a known carcinoembryonic 
antigen [42]–[44]. CEACAM1 has several distinguishable isoforms in mice, two of which 
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contain four extracellular domains, respectively, one significantly longer (CEACAM1-4L[ong]) 
than the other (CEACAM1-4S[hort}) [42]. The extracytoplasmic Ig-like domains and long and 
short cytoplasmic domains of the different CEACAM1 isoforms are shown in Figure 2 [45], 
[46]. Additionally, the human CEACAM1-L isoform contains ITIMs (Two immunoreceptor 
tyrosine receptor inhibition motifs), whereas ITSMs (Two immunoreceptor tyrosine-based 
switch motifs) in mouse CEACAM1-L result in a distinctive CEACAM1-L structure, which is the 
structural basis for CEACAM1 function and signal transduction (AKT, RIPK3) [47], [48]. As 
described above, negative signaling is mediated by ITIM-containing CEACAM1 (CEACAM1-L), 
whereas CEACAM1-S isoforms mediate positive signaling, and different quantitative 
relations of CEACAM1-L to CEACAM1-S expression are related to the development of 
different diseases [49]. CEACAM1 is expressed in a variety of cells, such as hematopoietic 
cells, epithelial cells as well as endothelial cells, which have different biological functions, 
such as cell adhesion as well as cell signaling. CEACAM1 impacts the immune response of the 
host and the integrity of epithelial cells and homeostasis, which is connected to cell 
proliferation and differentiation [50], [51]. 
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Figure 2  The structure of CEACAM1 protein (modified from [42])  
From left to right are the various major isoforms of CEACAM1, 1-4L, 1-4S, 1-3L and 1-3S. Red indicates the 
membrane, brown indicates the transmembrane domain long cytoplasmic tail (two regions on the left) and 
short cytoplasmic tail (two regions on the right), green indicates the N-terminal IgV-like domain and yellow 
indicates the IgC-like domains of A1, B and A2. 
 
1.2.2 CEACAM1 in vascular homeostasis 
CEACAM1 is also expressed in a lot of cells and tissues, such as immune cells and 
activated endothelial cells [42] [52]. During the last decade, a lot of evidence in vascular 
homeostasis has revealed that CEACAM1 plays a role in vascular remodeling, controlling the 
function of the endothelial barrier and in the formation of blood vessels [45][53]. 
 Vasculogenesis refers to the process by which undifferentiated mesodermal 
precursor cells form blood vessels [54]. VEGF (vascular endothelial growth factor) and the 
VEGFR1/2 (vascular endothelial growth factor receptor 1/2) ratio are critical for the 
 Introduction 9 
formation and differentiation of hemangioblasts into endothelial cells [55]. Some other vital 
molecules in vasculogenesis are cell adhesion molecules such as CEACAM1, as illustrated in 
research showing that CEACAM1 is expressed in rat brain vessels [56]. More recently, it has 
been shown that CEACAM1 is a potent stimulant of VEGF-mediated angiogenesis [57], [58] 
(Figure 3). The loss of CEACAM1 could, therefore, be expected to have serious implications 
for the growth of the vascular system; however, it has been demonstrated that 
vasculogenesis is unimpaired in Ceacam1˗/˗ mice [59]. This may be because there is another 
molecule that can substitute for CEACAM1 function during development in vivo. Taken 
together, this demonstrates a crucial role of CEACAM1 during vasculogenesis, while at the 
same time its role during development is redundant to some extent as Ceacam1˗/˗ mice are 
viable. 
 VEGF is an essential angiogenic regulator, therefore, CEACAM1 also plays an 
important role in the stimulation of endothelial cell proliferation and enhancing vascular 
permeability, which is an integral part of VEGF-mediated angiogenesis [59]–[61]. The 
regulation of vascular permeability is crucial for normal tissue integrity, hence, one of the 
pathological characteristics associated with tumor angiogenesis is abnormal vascular 
permeability. Cell adhesion molecules is very important to vascular morphogenesis as well as 
endothelial signaling in complex angiogenic systems. CEACAM1 is an adhesion molecule with 
pro-angiogenic activity and a major effector of VEGF. VEGF can upregulate the expression of 
CEACAM1, and anti-CEACAM1 antibodies block VEGF-induced angiogenesis [62]. Previous 
research revealed that the exogenous application of soluble CEACAM1 has angiogenic 
characteristics and can be used as a morphological effector of VEGF [57]. CEACAM1 also has 
an crucial function in the formation of vascular integrity as well as vascular networks in vivo, 
especially during normal neovascularization and is expressed in neovascularization during 
physiological angiogenesis, including endometrial hyperplasia and immature 
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neovascularization of different tumors [63], [64]. In a study in murine Ceacam1˗/˗ lung 
endothelial cells (MLECs), the VEGF-induced signaling pathway exposed a defective 
endothelial nitric oxide synthase signaling pathway with reduced nitric oxide production. 
“CEACAM1 is tyrosine-phosphorylated upon VEGF treatment in a SHP-1- and Src-dependent 
manner, and the ITIM motif of CEACAM1 is key to CEACAM1 phosphorylation and NO 
production” [65]. In summary, this links CEACAM1 to important VEGFR2/Akt/eNOS-
mediated vascular permeability pathways. 
 
 
Figure 3  CEACAM1 mediates angiogenesis through vascular endothelial growth factor  
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1.2.3 CEACAM1 in the immune system 
Numerous research have investigated the function of CEACAM1 in the immune system, 
including its role macrophages, neutrophils, in particular, in T cells and natural killer cells 
[66]–[69]. Function of CEACAM1 in the immune system is summarized in Figure 4. 
 CEACAM1 plays a regulatory function in some immune cells, particularly activated T 
cells where it is highly expressed in response to interleukin-2 (IL-2) stimulation [70], [71]. As 
outlined above, CEACAM1 comprises two subtypes, CEACAM1-L and CEACAM1-S. The main 
function of CEACAM1-L is to inhibit T cell activation, while CEACAM1-S promotes T cell 
activation [72], [73]. CEACAM1-L domain ITIMs mediate the inhibitory function of CEACAM1-
L, which do not exist in CEACAM1-S [74]. Above ITIMs are phosphorylated by a lot of Src-
associated tyrosine kinases, such as the recruited tyrosine phosphatases, SHP-1 (Src-
homology 1 domain-containing protein tyrosine phosphatase) as well as SHP-2 (Src-
homology 1 domain-containing protein tyrosine phosphatase). In summary, it has been 
shown that CEACAM1-L is an inhibitor of T cells through ITIM motifs and mediates its 
function via SHP-1 and SHP-2. CEACAM1 also functions along with TIM-3 (T-cell 
immunoglobulin and mucin-domain containing-3) in T cells. The exhausted phenotype of T 
cells is also demonstrated by CEACAM1 and TIM-3  co-expression [75]. TIM-3 and CEACAM1 
is co-expressed on T cells during tolerance induction, exhibits biochemical relationships with 
CEACAM1, as well as acts as a heterophilic CEACAM1 ligand [75]. CEACAM1 induces TIM-3 
localization on the T cell by promoting TIM-3 maturation, with double expression of 
CEACAM1 and TIM-3 being a biomarker of exhausted T cells. 
 NK cells are important lymphocytes for innate immunity as well as the expression of 
CEACAM1 protects against NK-mediated tumor cell killing. Several CEACAM1-mediated NK 
inhibition models have been proposed. Silencing of CEACAM1 in human cancer cells 
increases the level of NK cell surface activating ligands, whereas overexpression of 
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CEACAM1-3S prevents NK cells from being activated [76]. The expression of CEACAM1 on 
tumor cells leads to NK-mediated immune escape through shielding the ligand of the NK cell 
surface receptor, although CEACAM1-L inhibits NK cell activation is not fully understood, the 
impact is clear. 
 B cells are specialized antigen presenting cells (APC), the primary role of which is to 
secrete antibodies. CEACAM1 is engaged in the function of B cells, although there is some 
controversy on the role of CEACAM1 in this cell type [52], [77], [78]. Recent studies have 
shown that CEACAM1 is a crucial factor for the survival of B cells, affecting not only the 
number of B cells, but also their functionality as antibody producers [77], [79]. The effect of 
CEACAM1 on naive B cells is limited, whereas there is significant reduction in the number of 
mature B cells in CEACAM1 knockout mice [80]. CEACAM1 may therefore have crucial 
function in the survival of B cells specifically during the propagation of an immune response. 
The expression of CEACAM1 on human B cells is less clear; whereas, CEACAM1 does play a 
vital role in the human B cell line [78]. 
 In neutrophils, CEACAM1 plays an inhibitory role, although its role is more 
complicated in neutrophils than in other immune cells. CEACAM1 is expressed in a small 
proportion of resting neutrophils, where it is transferred from the intracellular environment 
to the cell surface after neutrophils have been activated [81], [82]. In addition, CEACAM1 
silencing can induce apoptosis of human neutrophils using the SHP1-mediated pathway. 
Consistent with this result, in tongue squamous cell carcinoma, CEACAM1 upregulation has 
been linked to neutrophil infiltration that is associated with poor clinical outcomes [83]. In 
addition, Ceacam1-deficient mice showed accelerated mortality compared with wild-type 
mice in neutrophil induced immunopathologies, indicating that neutrophil-induced 
immunopathological modifications occur without sufficient CEACAM1 expression, and 
indeed this phenotype is reversed by a restored expression of CEACAM1 [68]. 
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 The function of CEACAM1 in macrophages has been investigated and CEACAM1 can 
bind to macrophages to prevent apoptosis via the PI3K / AKT pathway [68]. 
 
Figure 4  Functions of CEACAM1 in the immune system (modified from [68]) 
B cell: B lymphocyte, SHP-1: Src homology region 2 domain-containing phosphatase-1, PI3K: 
phosphatidylinositol 3-kinases, AKT: Protein kinase B, Bcl-2: B-cell lymphoma 2, NK cell: Natural killer cells, T 
cell: T lymphocytes, CEA: Carcinoembryonic antigen. 
 
1.2.4 CEACAM1 in kidney disease 
Most data on the functions of CEACAM1 in the kidney are derived from studies on 
renal cell carcinoma. Initial studies have demonstrated that CEACAM1 is expressed in renal 
epithelial cells(proximal tubular), whereas clear cell carcinoma is generated from proximal 
renal tubules [84]. Therefore, CEACAM1 can be considered to regulate the immunogenicity 
of renal cell carcinoma and expression was downregulated in almost all patients with renal 
cell carcinoma, and this type of downregulation was comparable to other cancers [85], [86]. 
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Importantly, the complete loss of CEACAM1 expression has also been noted in renal 
adenomas, indicating that CEACAM1 downregulation or loss is an early occurrence in the 
development of renal cell carcinoma [85]. This observation strongly indicates that CEACAM1 
plays a vital role in tumor suppression in renal cell carcinoma. 
Acute renal injury (AKI) often caused by ischemia / reperfusion (IRI), sepsis and toxins, 
is a prevalent medical complication globally with high morbidity and mortality [83], [87]. AKI 
is related to a poor prognosis despite advancements in kidney replacement therapy. AKI is a 
condition of rapid renal excretion failure, frequently accompanied by oliguria that usually 
occurs within hours or days. Recovery of renal function is common in most patients; 
however, many still require dialysis or have severe renal impairment. Because high mortality 
rates are associated with serious AKI, this pathology should not be overlooked clinically. To 
date, there is limited research on the role of CEACAM1 in kidney nephritis. Recently, one 
study [88] showed that the NLRC5 (NOD-like receptor family CARD domain containing 5) 
negatively regulates CEACAM1 and leads to tubular epithelial cell death through the 
PI3K/AKT pathway, ultimately leading to AKI, as shown in Figure 5. However, the is 
insufficient knowledge about CEACAM1 and its function in the kidney, other than during 
tumorigenesis [89]–[93]. Therefore, the role of CEACAM1 in renal biology, especially under 
inflammatory conditions such as anti-GBM disease needs further clarification. 
CEACAM1 has been found to play a vital role in the immune response, but to date, no 
research has been reported on the involvement of CEACAM1 in anti-GBM nephritis. My 
thesis will focus on the function of CEACAM1 in anti-GBM nephritis. 
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Figure 5  NOD-like receptor family CARD domain containing 5 aggravates acute kidney injury by regulating 
CEACAM1 the signaling pathway 
NOD-like receptor family CARD domain containing 5 leads to renal injury through promoting tubular epithelial 
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1.3 Aims of this thesis project 
As described in previous studies, CEACAM1 plays a role in many physiological settings, 
such as tumor and vascular homeostasis. We aimed here to characterize its role during 
kidney inflammation by using human and murine tissue sections from normal and 
inflammatory conditions as well as Ceacam1-/- mice and the use of anti-GBM disease.  
First, the expression of CEACAM1 in normal mouse and human kidneys was compared 
to diabetic nephropathy as well as anti-GBM disease. 
To further explore the function of CEACAM1 in anti-GBM disease, anti-GBM disease 
was induced in Ceacam1+/+ and Ceacam1-/- mice and their phenotypes were compared. 
Finally, In vitro experiments were performed to investigate the deeply mechanisms of the 
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1.4 Hypotheses 
Anti-GBM disease is a rare vasculitis that affects the renal and pulmonary capillary 
beds. This is a typical autoimmune disease induced by direct pathogenic autoantibodies that 
target a specific autoantigen expressed in the basement membrane of these organs; 
however, the reasons for, and the mechanisms by which, these autoantibodies are produced 
remain unclear. Clinically, the means of controlling GBM are still limited, with the current 
main methods being plasma exchange and immunosuppressive therapy. 
CEACMA1 plays a different role in various inflammatory reactions and diseases, 
functioning as an anti-inflammatory factor or a pro-inflammatory factor depending on the 
cellular context. 
However, the role of CEACAM1 in anti-GBM disease remains unclear. My project 
aimed to explore the role of CEACAM1 in anti-GBM nephritis to test the hypotheses below: 
 
I hypothesized that 
1. CEACAM1 plays a pathogenic role in the heterologous anti GBM disease mouse model of 
crescentic anti-GBM nephritis. 
2. CEACAM1 deficiency protects against anti-GBM nephritis and prevents further 
development of the disease and this effect is likely mediated by CEACAM1 on endothelial 
cells. 
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2 Materials and methods 
__________________________________________________ 
2.1 Animal experiments 
2.1.1 Mice 
C57/BL6/J SJA Laboratory Animal company/ Changsha/C 
Ceacam1-/- C57/BL6/J  PD Dr. Bernhard B. Singer/ UK Essen 
 
2.1.2 Mice housing 
Standard chow  SJA Laboratory Animal company/ Changsha/ C 
Bedding  SJA Laboratory animal company/ Changsha/C 
Nestlets SJA Laboratory animal company/ Changsha/C 
Makrolone cages (type 2) SJA Laboratory animal company/ Changsha/ C 
Polycarbonate retreats SJA Laboratory animal company/ Changsha/C 
  
2.1.3 Mice genotyping 
Magnesium-chloride hexahydrate  Merck/ Darmstadt/ G 
Potassium-chloride MSDS  Merck/ Darmstadt/ G  
Gelatine solution Sigma-Aldrich/Munich/ G 
Proteinase K Merck/ Darmstadt/ G 
TRIS hydrochloride  Roth/ Karlsruhe/ G  
NP-40 Sigma/ Munich/ G 
10 XThermopol buffer  New England BioLabs/ Frankfurt/ G  
Tween20 Sigma/ Munich/ G 
Taq/DNA/Polymerase New England BioLabs/ Frankfurt/ G 
dNTP Mix (1,25mM) Fermentas/ St. Leon-Rot/ G 
Agarose  Invitrogen/ Karlsruhe/ G 
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Ethidium bromide solution Sigma/ Munich/ G 
Bromophenol/blue  Roth/ Karlsruhe/ G 
Glycerine (1L) Fermentas/ St. Leon-Rot/  
Xylene-cyanol FF G Roth/ Karlsruhe/ G 
DNA/ladder  Sigma/ Munich/ G 
TRIS (500g) Roth/ Karlsruhe/ G 
Boric-acid powder Roth/ Karlsruhe/ G 
 
2.1.4 Narcosis, injectables, sacrifice 
Revertor  CP-Pharma/ Burgdorf/ G  
Isofluran-Forene Abbott/ Wiesbaden/ G 
Vaporizer for Forene (100 Series) Smiths Medical PM/ Norwell/ America 
Surgical/forceps  Medicon/ Tuttlingen/ G  
Anatomical/forceps Medicon /Tuttlingen/ G 
Scalpel  Pfm medical ag/ Cologne/ G  
Scissors (Surgical) Medicon/ Tuttlingen G 
Sheep anti-rat GBM serum Probetex Inc./ San Antonio/ America 
Clip/Applying/Forceps Medicon/ Tuttlingen/ G 
  
2.1.5 Mice blood collecting 
Eppendorf-tubes (1,5 ml) TPP/ Trasadingen/ Switzerland  
Micropipettes(20µl) Brand/ Wertheim/ G 
EDTA Biochrom KG/ Berlin/ G 
  
2.1.6 Organ removal 
Shandon-Formal-Fixx (10%) Thermo Fisher Scientific/ Waltham/ America  
 Casettes NeoLab/ Heidelberg/ G 
RNAlater®Storage Solution life Technologies/ Darmstadt/ G 
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2.1.7 Serum tests 
Mouse Albumin ELISA Kit  Bethyl Laboratories/ Montgomery/ American  
BUN kit DiaSys Diagnostic Systems/ Holzheim/ G 
Creatinine kit DiaSys Diagnostic Systems/ Holzheim/ G 
2.1.8 Histological staining and analyses 
Ethanol Solution  Merck/ Darmstadt/ G 
Ammoniumpersulfate  Bio-Rad Munich G 
Xylenes Merck/ Darmstadt/ G 
Periodic acidSchiff  Bio-Optica/ Mailand/ Italy  
Paraffin Powder Merck/ Darmstadt/ G 
Masson Goldner’s Trichrom kit  Morphisto/ Frankfurt/ G  
Methanol Solution Merck/ Darmstadt/ G 
H2O2 Biosciences/ San Diego/ America  
Weigert‘s iron hematoxylin Morphisto/ Frankfurt/ G 
Hematoxylin Merck/ Darmstadt/ G 
Eosin  Sigma/Aldrich/ St. Louis America 
Thiosemicarbazide Sigma/Aldrich/ St. Louis/ America 
Methenamine  Sigma/Aldrich/ St. Louis/America  
Disodium Tetraborate  Carl Roth/Karlsruhe/ G  
Silver-nitrate Sigma/Aldrich/ St. Louis/America 
Formaldehyde Solution Fisher/ Waltham/America 
Hydrogen-Nitrate Sigma/Aldrich/ St. Louis/ America 
Avidin powder  Vector/ Burlingame/ America  
GoldChloride Sigma/ St. Louis/ America 
Antigen/unmasking  Vector/ Burlingame/America 
Periodic/acid Sigma/Aldrich/ St. Louis/America 
Methyl green  Sigma/ Munich/ G  
ABC substrate solution kit Vector/ Burlingame/ America 
VectaMount® mounting medium Vector/ Burlingame/ America 
Biotin powder  Vector/ Burlingame/ America 
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Anti-F4/80 -Antibody  Bio-Rad / Hercules/ America  
Lotus tetragonolobus lectin (LTL) Vector Labs/ Burlingame/ America 
Anti-CEACAM1 -Ab  Prof. B. Singer/ Essen/ G  
Anti-neutrophil/Ly6B.2-Antibody BioRad/ Munich/ G 
Fibrinogen  Abcam/ Cambridge/ UK  
SuperFrost+® adhesion slides Menzel / Braunschweig/ G 
TUNEL kit Roche/ Mannheim/ G 
Anti-CD31-Antibody Dianova/ Hamburg/ G 
WT-1 Cell signaling/ Danvers/ MA 
Mac-2 Cedarlane/ ON/ Canada 
Anti-THP-Antibody Cedarlane/ Burlington/ Canada 
Nephrin Acris Antibodies GmbH/ Herford/ G 
 
2.1.9 Cell culture 
96-well plates TPP/ Trasadingen/ Switzerland  
24-well plates Nunc/ Wiesbaden/ G 
6-well plates Costar Corning/ Schiphol/ Netherlands 
RIPM-medium  GIBCO/Invitrogen/ Paisley/ UK  
DMEM-medium Invitrogen/ Karlsruhe/ G 
8-well arrays (ECIS) Ibidi/ Martinsried/ G 
Tubes (1.5, 2 mL)  TPP/ Trasadingen/ Switzerland  
Ultrapure- FCS Hyclone/ Logan/ America 
Cell culture dishes (35x10mm)  Becton Dickinson/ Franklin Lakes/ America  
 PBS Solution(1x) PAN Biotech/ Aidenbach/ G 
Fetal bovine serum Biochrom KG/ Berlin/ G 
Tubes (15, 50 mL) TPP/ Trasadingen/ S 
Tissue culture flasks 150 cm2 TPP/ Trasadingen/ S 
Penicillin - Streptomycin PAA Laboratories/ Pasching/ Austria 
Plastic histocasettes  NeoLab/ Heidelberg/ G  
Cell culture dishes (100x20mm) TPP/ Trasadingen/ S 
Cell culture dishes (150x20mm) TPP/ Trasadingen/ S 
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Needles Drogheda/ Ireland  
Pipette’s tip （1-1000μL） Eppendorf/ Hamburg/ G 
Microscope slides Menzel-Gläser/ Braunschweig/ G 
Syringes Becton Dickinson/ Heidelberg/ G 
Preseparation Filters Miltenyl Biotec/ Bergish Gladbach/ G 
   
2.1.10 Reverse-transcriptase-quantitative polymerase chain reaction 
2.1.10.1 RNA Isolation 
100 % Ethanol  Merck/ Darmstadt/ G  
RNAse/free DNase  Qiagen- Strasse 1 / Hilden/ G 
RNA Kit Ambion/ Darmstadt/ G 
-Mercaptoethanol Roth/ Karlsruhe/ G 
  
2.1.10.2 cDNA Synthesis 
Reverse Transcriptase “SS-II“5 Invitrogen/ Karlsruhe/ G  
Diethylpyrocarbonate  Sigma/ München/ G  
0,1 M Dithiothreitol Invitrogen/ Karlsruhe/ G 
Hexanucleotide-Mix Roche/ Mannheim/ G  
linear acrylamide  Ambion/ Darmstadt/ G 
25 mM dNTPs GE Healthcare/ Munich/ G 
RNAsin Promega/ Mannheim/ G 
x FS buffer solution Invitrogen/ Karlsruhe/ G 
 
2.1.10.3 Quantitative polymerase-chain reaction 
Bovine serum albumin  Fermentas/ St. Leon-Rot/ G  
PCR optimization kit Bitop-AG/ Witten/ G  
dNTPs/25 mM Fermentas/ St. Leon-Rot/ G 
Taq-buffer/10x Fermentas/ St. Leon-Rot/ G 
SYBRgreen I Sigma/ Munich G 
96-well plates/LightCycler  Roche/ Mannheim/ G 
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PCR-Primer/300 nM Metabion/ Martinsried/ G  
MgCl2/25 mM Fermentas/ St. Leon-Rot/ G 
  
2.1.11 Chemicals 
Bovines Serum Albumin  Roche Diagnostics/ Mannheim/ G  
Potassium-dihydrogenphosphate Merck/ Darmstadt/ G 
DEPC  Fluka/ Buchs/ Switzerland  
Sodium-acetate Merck/ Darmstadt/ G 
TEMED  SCBT/ Santa Cruz/ CA 
Sodium-citrate Merck/ Darmstadt/ G 
Penicillin  Sigma/ Deisenhofen/ G  
Disodium-hydrogenphosphate Merck/ Darmstadt/ G 
Tissue Freezing Medium  Leica/ Nussloch/ G  
Potassium-hydroxide Merck/ Darmstadt/ G 
DMSO Merck/ Darmstadt/ G 
EDTA Calbiochem/ SanDiego/ America 
Sodium-chloride Merck/ Darmstadt/ G 
Ethanol Merck/ Darmstadt/ G 
Formalin Merck/ Darmstadt/ G 
NAOH (5N) Merck/ Darmstadt/ G 
Sodium-dihydrogenphosphate  Merck/ Darmstadt/ G 
Calcium hydroxide  Merck/ Darmstadt/ G 
Calcium dihydrogenphosphate Merck/ Darmstadt/ G 
Calcium chloride Merck/ Darmstadt/ G 
Isopropanol Merck/ Darmstadt/ G 
Streptomycin Sigma/ Deisenhofen/ G 
Potassium-chloride powder Merck/ Darmstadt/ G 
HCl (5N) Merck/ Darmstadt/ G 
2.1.12 Western blotting 
Bradford reagent  BioRad/ Munich/ G  
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Protein standard BioRad/ Munich/ G 
Complete™ Protease-Inhibitor Roche Life Science/ Basel/ Switzerland 
Rabbit anti-mouse p-AKT Ab  Cell Signaling/ Danvers/ America  
RIPA buffer solution Sigma/Aldrich/ St. Louis/ America 
Goat anti-rabbit IgG/HRP-linked  Cell Signaling/ Danvers/America  
Beta-mercaptoethanol GE Healthcare/ Amersham/ UK  
ECL-WB Detection Kit  Millipore/ Schwalbach/ G 
TEMED  BioRad/ Munich/ G  
Filter Whitman papers  Millipore/ Schwalbach/ G 
Acrylamide  Carl Roth/ Karlsruhe/ G  
Agarose  MP Biomedicals/ Eschwege/ G  
TAE Sigma/ St. Louis/American 
Nonfat dried milk powder RanReac-AppliChem/ Poligon/ Spain 
Ammoniumperoxodisulfate BioRad/ Munich/ G 
Protein-Marker IV PeqLab/ Erlangen/ G 
Stripping-Buffer Restore™ ThermoFisher/ Waltham/America 
 Immobilon®-PVDF membrane Carl Roth/ Karlsruhe/ G 
Bromphenolic blue Merck/ Darmstadt/ G 
Rabbit anti-mouse beta-actin Ab Cell Signaling/ Danvers/America 
SDS BioRad/ Munich/ G 
Rabbit anti-mouse RIPK3 antibody Cell Signaling/ Danvers/America 
 
2.1.13 Murine primer sequences 
Murine Forward (5'-3') Reverse (5'-3') 
18s GCAATTATTCCCCATGAACG AGGGCCTCACTAAACCATCC 
NGAL ATGTCACCTCCATCTGG GCCACTTGCACATTGTAG 
KIM1 TGGTTGCCTTCCGTGCTCT TCAGCTCGGGAATGCACAA 
TIMP2 GCAACAGGCGTTTTGCAATG AGGTCCTTTGAACATCTTTATCTGC 
COL1A1 ACATGTTCAGCTTTGTTGAC TAGGCCATTGTGTATGCAGC 
TNF-a AGGGTCTGGGCCATAGAACT CCACCACGCTCTTCTGTCTAC 
CEACAM1 CCTCTATTCCAGGAAGTCTGGC GTTCAGGACAGTGTATGCGACG 
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TIE1 GGCAGCATGAAACTTCGCAAGC ACCAGAAGTCGATACGCGGCAT 
TIE2 GAACTGAGGACGCTTCCACATTC TCAGAAACGCCAACAGCACGGT 
ANG1 AACCGAGCCTACTCACAGTACG GCATCCTTCGTGCTGAAATCGG 
ANG2 AACTCGCTCCTTCAGAAGCAGC TTCCGCACAGTCTCTGAAGGTG 
CCL5 CCTGCTGCTTTGCCTACCTCT ACACACTTGGCGGTTCCTTCG 
IL-10 CCAAACCAGTCTGAGAGCACCT CAGGACAATGCCTGAGCCTTTC 
CCL2 CCTGCTGTTCACAGTTGCC ATTGGGATCATCTTGCTGGT 
CXCL1 TCCAGAGCTTGAAGGTGTTGCC CAAAGAGGAGGTCAGCCACTGA 
CXCL2 CATCCAGAGCTTGAGTGTGACG GGCTTCAGGGTCAAGGCAAACT 
VEGF  CTGCTGTAACGATGAAGCCCTG GCTGTAGGAAGCTCATCTCTCC 
VEGFR1 TGGATGAGCAGTGTGAACGGCT GCCAAATGCAGAGGCTTGAACG 
VEGFR2 CGAGACCATTGAAGTGACTTGCC TTCCTCACCCTGCGGATAGTCA 
CEACAM1L GCCATGCAGCCTCTAACCCACC CTGGAGGCTGAGGGTTTGTGCTC 
CEACAM1S GCCATGCAGCCTCTAACCCACC TCAGAAGGAGCCAGACCCGCC 
ZO-1                             GTTGGTACGGTGCCCTGAAAGA GCTGACAGGTAGGACAGACGAT 
Occludin TGGCAAGCGATCATACCCAGAG CTGCCTGAAGTCATCCACACTC 
Claudin-5 TGACTGCCTTCCTGGACCACAA CATACACCTTGCACTGCATGTGC 
Claudin-12 GGACTCTGCTTCCTAACTGGAG TCAGGCAGTCACTGCTTCCATC 
Claudin-15 AACTGCTGGGACTTTCCGTCCA TGGAGAGATCCATGTTGCCCAC 
   
2.1.14 Machines for experiment 
2.1.14.1 ELISA reader 
ELISA/reader Tecan  Tecan/ Crailsheim 
  
2.1.14.2 Cell culture 
ECIS Z-Theta  Ibidi/ Martinsried/ G  
Neubauer-counting chamber  Roth/ Karlsruhe/ G 
Mycoplasma Detection Kit  ThermoFisher/ Waltham/America  
Laminar flow hood Class Baker Company/ Sanford/America 
Incubator (Type B5060 EC-CO2) Heraeus Sepatech/ Osterode 
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2.1.14.3 Microscopy  system and microtome  
Digital camera (DC 300F) Leica Microsysteme/ Cambridge/ UK  
Light microscope Leica Wild (MPS52) Leica Microsystems/ Wetzlar 
Light microscope Leica (DMRBE) Leica Microsystems/ Wetzlar 
Microtome Jung (CM 3000)  Leica/ Solms  
 
2.1.14.4 Nucleic acid analysis 
Rotilabo®-Mikropistill  Carl Roth GmbH/ Karlsruhe/ G  
Thermomixer (5436)  Eppendorf/ Hamburg/ G 
PCR-Gelchamber  PeqLab Biotechnologie/ Erlangen/ G  
Photometer-Ultrospec (1000)  Amersham/ Freiburg/ G  
Photometer-DU (530) Beckman Coulter/ Fullerton/America 
PCR machine (LightCycler 480) Roche Diagnostics/ Mannheim/ G 
Thermo cycler (UNO-II) Biometra/ Saxony/ G 
 
2.1.15 Machine for centrifuges 
Heraeus/ Biofuge primo  Kendro Laboratory Products GmbH/ G  
Centrifuge-5415 C  Eppendorf/ Hamburg/ G 
Heraeus/ Minifuge T  VWR International/ Darmstadt/ G  
Centrifuge-5418 Eppendorf/ Hamburg/ G 
Centrifuge-Megafuge (1.0R) Heraeus Sepatech/ Osterode/ G 
  
2.1.15.1 Smaller balances 
Benchtop Mettler(PJ 3000)  Mettler Toledo/ Giessen/ G  
Benchtop BP (110S) Sartorius/ Saxony/ G 
  
2.1.15.2 Other devices 
Olympus (BX50)  Olympus Microscopy/ Hamburg/ G  
Pippet-Pipetman  Gilson/ Middleton/America 
Tecan/ GENios Plus  Tecan/ Crailsheim/ G  
pH meter WTW GmbH/ Weilheim/ G 
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Water bath (HI1210) Leica Microsysteme/ Solms 
Pipet tips Peske/ Aindling-Arnhofen 
Leica (DC 300F) Leica Microsystems/ Cambridge/ UK 
Vortex Scientific Industries/ Bohemia/ America 
  
2.1.15.3 Software 
Inkscape 0.92.3 Inkscape  
CellQuest  BD Biosciences/ Heidelberg/ G 
Adobe-Illustrator (cc 2017) Microsoft/ Redmond/America  
Windows 10 Software  Microsoft/ Redmond/America 
QWinows Leica Microsystems/ Wetzlar 
Office (2017) Adobe/ California/America 
Adobe-photoshop (cc 2017) Adobe/ California/ America 
Endnote (x8) Thomson-Reuters/ New York/ America 
Mendeley Mendeley/ London/ UK 
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2.2 Animal experiments 
2.2.1 Mice housing 
It more diffuse that the care followed the standards of the institution (The department 
of Cancer Research Institute, Central South University). Before use, mouse retreats, nestlets, 
bedding, cages, water and food were autoclaved for sterilization. Mice were housed in a 
maximum of five in filter-top cages with unlimited access to water and food under specific 
pathogen free conditions as well as a 12-h dark-light cycle. All experimental procedures 
detailed below were conducted in strict compliance with China’s equivalent of the National 
Institutes of Health’s Guide for the use of mice, and with approval from the Ethics 
Committee of Cancer Research Institute of Central South University. 
2.2.2 Genotyping 
Ear punch biopsies, obtained from mice using the earhole punching technique, were 
used to isolate DNA. The tissue was lysed on a shaker in 200 μl of PBND buffer (2.5 ml of 2 M 
KCl, 1 ml of 1 M Tris-HCl (pH-8.3), 0.25 ml of 1 M MgCl2, 10 ml of 0.1% gelatine, 0.45 ml of 
NP-40 (100%), 0.45 ml of Tween-20 (100%), and H2O up to 100 ml) containing 1 μl of 
proteinase K (20 mg/ml) for 4 hours at 56°C. Then the supernatant containing DNA was 
centrifuged for 2 min （12,000 g）, and  the supernatant (1 µl) was used in PCR, along with 
2 μl of either the CEACAM1 wild-type or CEACAM1 knockout primers (1 µl of forward and 
reverse primer) and PCR master mix (2.5 μl-10 PE buffer, 2.0 μl-1.25 mM dNTPs, 0.5 μl of 
Taq polymerase, 17.0 μl of H2O) in a reaction volume of 25 µl. Two reactions were set up per 
animal. Samples from known knockout and wild-type (WT) animals were used as controls 
and H2O was used as a no-template control instead of DNA. The reaction conditions were 
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94°C for 15 minutes, then 30 cycles of 94°C for 30 seconds, 61°C for 60 second and 72°C for 
90 seconds, finally extension step at 72°C for 10 minutes. Next, 4 μl of the PCR reaction was 
mixed with 6 loading buffer (3 ml of glycerol, 0.5 ml of 5% bromphenol blue, 0.5 ml of 5% 
xylenecyanol and 6 ml of H20) by gentle pipetting and the samples were then loaded onto an 
gel consist of ethidium bromide in TBE buffer (Tris: 108 g, boric acid: 55 g, EDTA: 5.84 g, 
H2O:10 L). Finally, gels were run at 200 V for 30 minutes, and a DNA ladder is used to 
estimate adequate separation of the fragments. 
2.2.3 Anti-GBM disease 
The anti-GBM mouse model (Figure 6) was established following a previously 
described protocol [94]. Anti-GBM serum for experiment was purchased from a company 
(Probetex Inc., San Antonio, USA) and was prepared in accordance with their protocol. A kit 
(Roche Diagnostics GmbH, Mannheim, G) was used to isolate the glomerulus, which was 
then injected into sheep to activate their immune system to produce anti-mouse glomerulus 
antibody. Serum was then gathered from the animals and stored at ˗80°C for future use. In 
experiments, 200 µl of serum was injected per mouse to induce anti-GBM disease and the 
same dose of PBS was injected for control mouse. 
To induce anti-GBM glomerulonephritis, male mice aged 8–10 weeks were injected 
with 200 µl of anti-GBM serum intravenously at day 0. The urinary protein concentration 
was evaluated at 24 h to confirm that the model had been successfully established. Urine 
and blood samples were collected at day ˗1, day 1 (d1) and day 7 (d7) to evaluate kidney 
damage. Mice were euthanized at the end and the kidneys were harvested. The anti-serum 
contained GBM antibodies, which bind GBM directly to the glomerular, causing the 
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supplementary system to be activated and glomerular and endothelial cell death at the two 
time points are shown in Figure 6. 
 
Figure 6  Mouse model of anti-GBM and the study design 
The mouse model of anti-GBM. Step 1: the glomerulus is isolated from rats, then antibody is injected into 
sheep. Step 2: serum is collected from sheep that contains anti-rat glomerulus antibody and this antibody is 
injected into mice to induce anti-GBM disease (A). Design of the mouse model. Two time points were selected 
for analysis, 24 h and 7 days. Mice were sacrificed at the end of the experiment (B). 
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2.2.4 Sacrifice 
At the respective endpoints (24 h and 7 days after anti-GBM serum injection), mice 
were anesthetized in a chamber (200 cm³, oxygen flow:1 L/minutes, alveolar 
concentration:2%–3%). Upon induction of surgical tolerance (no reaction to forceps 
stimulation of the paw), blood was drawn from the mouse's tail into an Eppendorf tube 
coated with 8 µl of EDTA. The mice were then euthanized by cervical dislocation. Mice were 
placed in a supine position; their limbs were fixed with syringe needles and 70% alcohol was 
sprayed evenly onto the skin. The kidneys were harvested after peritoneal cavity was 
opened. Next, the kidney was divided into three sections, the center portion was immersed 
in 4% formalin, the upper pole was snap/frozen (in liquid nitrogen) and transferred to ˗80°C 
storage for later protein analysis, while the lower pole was immersed in RNAlater for ˗20°C 
storage and subsequent RNA extraction. 
2.2.5 Colorimetric serum test 
Measurements of serum creatinine, urinary albumin/creatinine ratios , and blood urea 
nitrogen levels were performed according to the manufacturer’s instructions [95].  
2.2.6 Histological analysis 
Paraffinization of tissues 
The tissues that were already in histology cassettes were fixed overnight in 4% 
formalin and were then sequentially immersed in an increasing ethanol series (2 70%, 80% 
and 95%, and 3 100% ethanol) for 1 h each. Histology cassettes were then sequentially 
immersed in xylene (1.5 hours), three times, then two paraffin immersions at 60°C for 2 
hours each. For optimal sectioning results, tissues were then repositioned in the histology 
cassettes and integrated into a paraffin block, that was refrigerated at 0°C. The block was 
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sectioned in a water bath using a microtome into 2-μm-thick sections. Swimming sections 
were then carefully mounted onto slides covered with ammonium persulfate and were dried 
at 37°C for 12 h. 
PAS staining and scoring 
a) Deparaffinization in xylene as well as rehydration in ethanol solution (100% ethanol: 3 
times X 3 minutes, 95% ethanol: 2 times 3 minutes, 70% ethanol: 1 time 3 minutes). 
b) Tissue sections (of 2-μm thickness) were stained under full immersion (10 minutes with 
0.5% periodic acid) then rinsed in distilled water (2 times 5 minutes). 
c) Sections were immersed in Schiff reagent (20 minutes), then rinsed in distilled water 
(2times  5 minutes). 
d) Slides were covered in 0.55% potassium metabisulfite for 2 minutes, then rinsed with 
distilled water (2 times  5 minutes), counterstained in Mayer’s hemalaun reagent (3 
minutes) then washed with running water (10 minutes). 
e) Slides were dehydrated in ethanol solution (2 70%, 80%, 95% and 3 100% ethanol), 
then covered in VectaMount media and sealed with a coverslip after rapidly immersed in 
xylene. 
All of the kidney slides were scored according to the following protocol and scores in the 
results section are expressed as the mean ± SD. Tubular injury was assessed by digital 
Iimorphometry using the ImageJ software. Tubular casts were evaluated on sections in 20 
high-powered cortical fields per mouse. In total, 50 glomerular were assessed per mouse 
and the number of crescents was counted as shown in Figure 7. 
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Figure 7  Crescent formation in anti-GBM nephritis 
 Panels show different magnifications: 400 (Left) and 630 (Right). The black arrow represents the crescent. 
 
Masson-Goldner-Trichrom-staining and scoring 
The steps below were followed for Masson-Goldner-Trichrom staining and scoring: 
a) Deparaffinization in xylene as well as rehydration in ethanol solution (100% ethanol: 3 
times X 3 minutes, 95% ethanol: 2 times 3 minutes, 70% ethanol: 1 time 3 minutes). 
b) Weigert's iron hematoxyline: 2 μm tissue sections were stained (3 minutes), then rinsed 
with running water (10 minutes). 
c) Goldner solution I (Ponceau Acid Fuchsin): tissue sections were stained (10 minutes), then 
rinsed (1% acetic acid: 30 seconds) and analyzed after around2 min. 
d) Goldner solution II (Phosphomolybic Acid-Orange) was used for complete collagen 
bleaching, then slides were rinsed I (1% acetic acid: 30 seconds) then stained in Goldner 
solution III (5 minutes). 
e) After more than 5-minutes rinse (1% acetic acid), slides were dehydrated in ethanol 
solution (2 70%, 80%, 95%, and 3 100% ethanol), then covered in VectaMount media and 
sealed with a coverslip after rapidly immersed in xylene. 
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All slides were assessed by digital morphometry using ImageJ software. For each kidney, 20 
images were recorded per slide and the percentage positive area per side was quantified 
after threshold quantitation. 
Immunohistochemistry and scoring 
The steps below were followed for immunohistochemistry and scoring: 
a) Tissue was deparaffinized in xylene as well as rehydrated in ethanol solution (100% 
ethanol: 3 times X 3 minutes, 95% ethanol: 2 times 3 minutes, 70% ethanol: 1 time 3 
minutes). 
b) Tissue sections of 2 μm were washed with PBS (7 minutes) and blocked in methanol 
containing 3% H2O2 for 20 min. 
c) Sections were immersed in 1% antigen-unmasking solution and heated 4 for 2.5 min 
each in a microwave. 
d) After washing with PBS for another (7 minutes), sections were blocked in avidin (15 
minutes) and biotin (15 minutes). 
e) Primary antibody staining was performed overnight （4°C）. Sections were incubated in 
secondary antibodies（30 minutes）, After washing under PBS. 
f) After washing with PBS for another (7 minutes), each section was incubated with 0.1% PBS 
ABC substrate solution (30 minutes), followed by further washing under PBS then by Tris-HCl.  
g) Staining was visualized under incubation in DAB substrate then methyl green was used as 
a counterstain. 
h) Slides were dehydrated in ethanol solution (2 70%, 80%, 95%, and 3 100% ethanol), 
then covered in VectaMount media and sealed with a coverslip after rapidly immersed in 
xylene. 
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All slides were assessed by digital morphometry using ImageJ software. For each kidney, 20 
images were recorded per section, and Mac-2 and WT-1 positive cells were counted 
manually (20 glomeruli/each kidney section). The percentage of the area that was positive 
per slide was quantified after the threshold quantitation. 
Co-Immunofluorescence and scoring 
The steps below were followed for co-immunofluorescence and scoring: 
a) Tissue was deparaffinized in xylene as well as rehydrated in ethanol solution (100% 
ethanol: 3 times X 3 minutes, 95% ethanol: 2 times 3 minutes, 70% ethanol: 1 time 3 
minutes). 
b) Tissue sections of 2 μm were washed under PBS (7 minutes), immersed in 1% antigen-
unmasking solution and heated 4, for 2.5 min each, in a microwave. 
c) Slides were then washed under PBS for another (7 minutes), and sections were blocked in 
avidin and biotin (15 minutes, each solution). 
e) Sections were stained with primary antibody for 1 hour at room temperature. Sections 
were incubated in secondary antibodies (30 minutes), after washing under PBS. 
d) For immunofluorescence co-staining with (CD31 or TUNEL, then antibody staining was 
followed by CD31 or TUNEL enzyme incubation in accordance with the manufacturer’s 
instructions. 
f) Slides were dehydrated in ethanol solution (2 70%, 80%, 95%, and 3 100% ethanol), 
then covered in VectaMount media and sealed with a coverslip after rapidly immersed in 
xylene. 
All slides were assessed by digital morphometry using ImageJ software. For each kidney, 20 
images were recorded per slide, and the percentage of the positive cells was quantified after 
the threshold quantitation. 
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2.2.7 Western blotting  
Total protein was extracted from kidney using RIPA buffer with phosphatase and 
protease inhibitor for western blotting as described previously [96]. Gel castings were 
prepared according to previous protocols [96]. Proteins were separated slowly by 
polyacrylamide gel electrophoresis using 10% sodium dodecyl sulfate buffer, then 
transferred to PVDF (polyvinylidene fluoride) membranes. All membranes were blocked at 
room temperature (5% skim milk:2 hours), then membranes were incubated with primary 
antibodies against mouse AKT, p-AKT, RIPK3 and β-actin at 4°C overnight. Then membranes 
were washed with TBST buffer three times, they were incubated in peroxidase-conjugated 
anti-rabbit IgG secondary antibodies (1 hour at room temperature). After washing three 
times, protein bands were detected using an ECL kit as described previously [97]. Images 
were normalized and analyzed by ImageJ software. 
2.2.8 RNA isolation 
a) PureLink RNA Mini kits were used for RNA isolation in accordance with the manufacturer's 
guidelines [36].  
b) Tissue (1/3 of each kidney) was lysed by homogenization in RNAlater Solution containing 
1% beta-mercaptoethanol. Homogenates were vortexed to lyse cells and lysates were mixed 
1:1 with 70% ethanol. 
c) The sample (700 µl) was then centrifuged at room temperature (1200 g, 15 seconds). The 
flow-through was discarded and this was repeated until all of the sample had been 
processed.  
d) Washing buffer, I was used to wash the membranes once, then with washing buffer II 
twice, and then centrifuged to dry the membrane (12000 g, 2 minutes). 
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e) Membranes were incubated with RNAse-free water at room temperature for 1 min. 
f) Membranes were then centrifuged to elute the RNA into the recovery tube (12000 g, 2 
minutes). 
g) The quality and quantity of the total RNA was determined using the UV absorbance at 260 
nm. 
2.2.9 cDNA preparation 
a) To prepare cDNA, 2 µg of RNA (in RNAse-free water up to a total volume of 15 µl) was 
reverse transcribed. 
b) To achieve this, the 15 µl RNA solution was added to 7.5 µl of master mix (4.5 μl 5 
superscript II buffer, 0.45 μl 25 mM dNTPs, 1 μl 0.1 M DTT, 0.25 μl linear acylamide, 0.25 μl 
hexanucleotides, 0.5 μl RNAsin and 0.5 µl SuperScript II enzyme) and the mixture was 
incubated at 42°C for 90 min, followed by 5 min at 95°C. 
c) Then, 200 µl of RNAse-free water was used to dilute the concentration to a working 
concentration of 1:10, which was stored at ˗20°C for subsequent use. 
2.2.10 Quantitative real-time RT-PCR (qPCR) 
a) Samples were prepared for PCR by adding 2 µl of template to a well, followed by 18 μl of 
qPCR master mix (0.16 µl of 10 Taq buffer; 10 μl of 2 SYBRgreen, 0.6 µl of each specific 
primer (diluted 1:10) and 6.64 µl of H2O). 
b) cDNA amplification and detection were processed on a thermal cycler (LC480, Roche) 
using below standard protocol: 95°C initiation phase (10 minutes), 60°C annealing phase (20 
seconds) and 72°C amplification phase (20 seconds) for a total of 40 amplification cycles. 
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c) Efficiency corrected quantitation was conducted by the thermal cycler relay on external 
standard curves describing the target's PCR efficiencies and reference genes 
(ratio=EtargetΔCPtarget (control ˗ sample)/ErefΔCPref (control / sample)). 
2.2.11 Cell culture 
The GEC cells [98] as well as the Caco2 cells [99] were cultured under standard sterile 
conditions at 37°C and 5% CO2 in DMEM or RPMI-1640 media, 1% penicillin/streptomycin 
and 10% fetal bovine serum. All cells were tested routinely every 6 months for mycoplasm 
contamination as described previously [100]. Cells were split for later experiment before 
growing to around 80%–90% confluency, and for the same experiment approximately the 
same passage cells were used. 
2.2.12 Transwell permeability assay 
a) Endothelial cells (5  104) in 500 µl of DMEM were grown on the membrane of each 
transwell insert in a 24well plate. 
b) Then, 1 ml of endothelial growth medium was added to per well. 
c) Forceps were used to move the inserts into the medium and a lid was placed on the plate. 
d) The plate was incubated of 37°C until a cell monolayer had formed. 
e) Stimulator and bovine serum albumin were added to the transwell insert then the plate 
was incubated (37°C) for the desired time period. 
f) The medium was aspirated from the lower chambers, then the OD of the sample was 
measured at 485 nm and emission at was measured at 520 nm according to standard 
protocols. 
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2.2.13 Epithelial barrier testing via electric cell–substrate impedance 
sensing (ECIS) 
Caco2 cells (50,000 cells/well) were incubated at ECIS 8-well arrays with serum-free 
DMEM and were incubated overnight at 37°C. When the cells reached confluence, they were 
stimulated with histones (100 μg/ml) or PBS. Cell damage was examined under a microscope 
and the histones were removed after 6 h when the medium was changed. Then 40 µg/ml of 
CEACAM1 antibody or PBS solution was added to well. The capacitance value was set as 0 or 
1 just before the histones were added and immediately after medium exchange. The set-up 
for the ECIS assay is shown in Figure 8. 
 
Figure 8  Electric cell-substrate impedance sensing experiments 
Histone stimulation experimental set-up from human colon epithelial cells. Cells were seeded ECIS 8-well arrays, 
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2.2.14 Statistical analyses 
The data are shown as the mean ± SD, unless otherwise indicated. A Student's t-test 
was used to compare the differences between groups and one-way ANOVA was used to 
compare the differences between more than two groups. GraphPad Prism software, version 


























3.1 CEACAM1 expression in murine and human kidneys 
To characterize the renal expression CEACAM1 in mice and human, the online Kidney 
Interactive Transcriptomics (KIT) database built on healthy mice and human kidneys was 
assessed. Interestingly, CEACAM1 was expressed in murine healthy kidneys in a lot of 
different cell types including podocytes, macrophages and endothelial cells in mice, with 
about 4-6% of cells expressing CEACAM1 and the highest expression found in endothelial 
cells. (Figure 9A, B, C, D). In the human kidney, CEACAM1 is mainly expressed on distal 
tubule cells and proximal tubule cells (Figure 9E, F, G, H). Compared with mice, CEACAM1 
shows a lower expression in the human kidney. Taken together, CEACAM1 is expressed both 
in healthy murine and human kidneys, albeit in different cell types and at low levels. 








Figure 9  The distribution of CEACAM1 expression on normal mice kidney and healthy human kidney (From KIT 
database) 
 The total cells which they already analysis in this database (A, E), CEACAM1 distribution on those cells (B, F), 
the average percentage scale and percentage expression of CEACAM1 on those cells (C, D, G, H). EC, 
endothelial cell; t-SNE, t-Distributed Stochastic Neighbor Embedding; LOH (DL), loop of Henle, distal limb; P, 
one podocyte population; PT, proximal tubule; DT, distal tubule; Mono, monocyte; IC, intercalated cells; LOH 
(AL), loop of Henle, ascending limb; Pod, podocytes; CD, collecting duct; 
 
3.2 CEACAM1 is upregulated in murine experimental glomerulonephritis 
To further characterize the role of CEACAM1 in glomerulonephritis, CEACAM1 
expression was analysed in kidneys at day 1 and day 7 after the induction of anti-GBM 
disease. Ceacam1 mRNA levels were significantly upregulated at day 7 compared to healthy 
kidneys (about six-fold) and there was also a non-significant trend towards upregulation on 
day 1 (Figure 10).  






Figure 10  Ceacam1 expression in mice kidney after induced anti-GBM disease 
Ceacam1 expression change in kidneys after induced Anti-GBM disease and normal mice kidneys. * p<0.05. 
3.3 CEACAM1 expression in human renal disease 
As CEACAM1 expression is upregulated during murine anti-GBM disease, CEACAM1 
expression was assessed in human anti-GBM disease. In order to use histology specimens, a 
CEACAM1 immunohistochemistry staining was established. Indeed, CEACAM1 staining was 
significantly increased in human anti-GBM disease compared to healthy kidneys (Figure 
11A+C). Interestingly, this effect seems to be somewhat disease-specific, as diabetic kidneys 
did not show any significant expression change compared to healthy control (Figure 11A+C). 
CEACAM1 is expressed in endothelial cells (white arrow, Figure 12 D) rather than other cells 




such as podocytes (black arrow, Figure 12 D). Taken together, these results are consistent 
with the finding of CEACAM1 upregulation in mice during anti-GMB disease.  
 
Figure 11  CEACAM1 expression in human kidney 
(A) CEACAM1 staining on human healthy kidney (HHK). (B) the picture of CEACAM1 staining of human diabetic 
kidney. (C) CEACAM1 expression staining on human Anti-GBM disease from biopsy. (D) IgG staining as negative 
control (ctrl) for normal human kidneys. (E) Quantification statistics for CEACAM1 staining (n=5 for healthy 
kidney, diabetic kidney, and anti-GBM disease kidney, respectively). **P<0.01, ***P<0.001. 
 
 





Figure 12  The location of CEACAM1 in human Anti-GBM kidney disease 
The amplifying picture of CEACAM1 in human Anti-GBM disease kidneys, from A to D is x200, x400, x630 and 








3.4 Ceacam1 deficiency ameliorates glomerular basement damage in 
murine glomerulonephritis 
3.4.1 Ceacam1 deficiency reduces albuminuria without affecting 
glomerular filtration rate 
To establish the exact role of Ceacam1 in glomerulonephritis, Anti-GBM disease was 
induced in both wild type and Ceacam1-/- mice. Of note, Ceacam1-/- mice showed 
significantly decreased albuminuria both at day 1 and day 7 compared to wild-type controls 
(Figure 13a).  When serum BUN was significantly increased in wild-type mice compared to 
Ceacam1-/- mice at day 7 (Figure 13B). However, serum creatinine was measured, no 
difference was found according to the Ceacam1 genotype at either d1 or d7 (Figure 13C). As 
there was a small difference in baseline serum creatinine values, glomerular filtration rate 
(GFR), which is the most sensitive marker for acute renal injury also in GN, was additionally 
measured. GFR results show that CEACAM1 does not affect GFR decline as well as recovery 
(Figure 13D). Together, Ceacam1 deficiency prevents renal injury in GN as evident by 
albuminuria while not affecting serum retention parameters and GFR.  





Figure 13  Effect of CEACAM1 on albuminuria, BUN, creatinine and GFR  
(A) CEACAM1 deficiency reduce the albuminuria of mice and (B) reduce the blood urea nitrogen of mice. (C) but 













3.4.2 Ceacam1-deficient mice show less glomerular crescents and 
tubular cast formation 
To investigate the effect of CEACAM1 on crescent and tubular cast formation, the 
number of crescents per 50 glomeruli and the area of the tubular casts per kidney were 
measured. Compared to wild-type mice, Ceacam1-/- mice show significantly less crescent and 
tubular cast formation at day 7 (Figure 14,15). Consistent with a previous study [36], no 
crescents or tubular casts were found at day 1. Thus, Ceacam1 deficiency prevents the 
formation of crescents and tubular cast in murine GN. 
 
Figure 14  Glomerular crescent formation after induced Anti-GBM disease 
(A, B, D and E) represent section for wild-type day1, Ceacam1-/- day 1, wild-type day 7 and Ceacam1-/- day 7, 
respectively. Quantification data for day 1 (C) and day 7 (F). ** p<0.01. 
 





Figure 15  Tubular casts formation after induced Anti-GBM disease 
A, B, D and E represent section for wild-type day1, Ceacam1-/- day 1, wild-type day 7 and Ceacam1-/- day 7, 
respectively. Quantification data for day 1 (C) and day 7 (F). *** p<0.0001. 
3.5 Ceacam1-deficient mice show less intra-renal injury 
Serum creatinine is a noticeable indicator of renal function and has become a 
significant indicator of kidney disease and injury. However, it is not a sensitive marker 
because serum creatinine concentrations do not dramatically change until renal damage is 
widespread [101]. NGAL, KIM-1, TIMP2 and IGFBP7 are currently accepted biomarkers for 
kidney injury. Ngal, Kim-1, Timp2 and Igfbp7 mRNA levels were significantly upregulated at 
day 7 (but not day 1) after GN induction, with wild-type mice generally expressing higher 
levels than Ceacam1-/- mice: Ngal and Kim-1 nearly five-fold, Timp2 about two-fold and 
Igfbp7 about 1.3-fold (Figure 16). By and large, CEACAM1 aggravates kidney damage as 
measured by intra-renal injury marker expression during Anti-GBM disease progression. 





Figure 16  Injury marker expression was upregulated after being induced in anti-GBM disease 
Ngal, Kim-1, Timp2 and Igfbp7 are increased more in the wild- type group on day 7. (A) kidney injury biomarker 
neutrophil gelatinase-associated lipocalin (NGAL) enhanced in GN, (B) kidney injury biomarker kidney injury 
molecule-1 (KIM-1) enhanced in GN. (C) The G1 cell cycle inhibitors tissue inhibitor metalloproteinase-2 (TIMP2) 












3.6 Ceacam1 deficiency decreases intra-renal expression of inflammatory 
markers and fibrosis 
As GN is primarily an inflammatory disease, the expression of the inflammatory 
cytokines CCL2, TNF-alpha, CCL5, CXCL1 and CXCL2 was assessed next. In keeping with the 
previous findings, Ceacam1-/- mice showed significantly less intra-renal inflammatory 
cytokine expression, and for CCL2 and TNF-alpha the difference reached statistical 
significance already on day 1 (Figure 17). While I did not observe any difference in intrarenal 
CD3+ or CD19+ cells between Ceacam1-/- and Ceacam1+/+ mice (Data not show). 
To assess the fibrosis induced by GN induction, intra-renal COL1A1 expression was 
assessed along with Sirius red staining of renal tissue sections. While a significant reduction 
on intra-renal COL1A1 expression was observed in Ceacam1-/- mice (Figure 17F), no 
difference was found between Ceacam1-/- and Ceacam1+/+ mice in Sirius red staining of 
glomeruli (Figure 18). This suggests that differences in diffuse tubulointerstitial fibrosis 
secondary to renal inflammation account for the difference in COL1A1 expression rather 
than glomerulosclerosis. 
 





Figure 17  Inflammation and fibrosis biomarker expression was upregulated after being induced in anti-GBM 
disease 
CCL2, TNF-alpha and COL1A1 maker are increased more in wild- type group on both day1 and day 7, CCL5, 
CXCL2 and CXCL1 are enhanced more  in the wild type group on day7.A: Chemokine (C-C motif) ligand 2 (CCL2) 
increased in GN,B: Chemokine (C-C motif) ligand 5 (CCL5) increased in GN,C: Tumor Necrosis Factor alpha (TNF-
alpha) increased  in GN,D: Chemokine (C-X-C motif) ligand 2 (CXCL2) increased  in GN,E: Chemokine (C-X-C 
motif) ligand 1 (CXCL1) increased in GN,F: Collagen Type I, alpha 1 (COL1A1) ) increased in GN. 
*p<0.05,**p<0.01. 






Figure 18  Fibrosis formation after induced in nephritis mice model 




















3.7 CEACAM1 mediates podocyte loss during murine Anti-GBM disease 
Podocytes play an vital role in glomerular function which form a filtration barrier with 
the glomerular capillary loop endothelial cells and the glomerular basement membrane 
[102]. Albuminuria was found in after induction of Anti-GBM disease, indicating filtration 
barrier damage. To further understand which part of the filtration barrier is damaged, 
podocytes were counted (based on WT1 positivity). Again, while no difference could be seen 
at day 1, Ceacam1-/- mice show less podocyte loss compared to wild-type mice at day 7 
(Figure 19). Thus, CEACAM1 signaling may influence the survival of podocytes in Anti-GBM 
disease. 
 
Figure 19  WT1+ staining for podocytes after induced in Anti-GBM disease in mice 
(A, B, C and D) WT1+ staining for podocytes of WT day 1, Ceacam1-/- day 1, WT day 7 and Ceacam1-/- day 7, 
respectively. (C and F) quantitation data of those section. **p<0.01. 




3.8 Ceacam1 deficiency attenuates renal leukocyte recruitment 
Another significant source of pro-inflammatory cytokines in glomerular diseases are 
activated mononuclear phagocytic cells, such as macrophages. CEACAM1 increases the 
number of macrophages (Mac-2 positive cells) infiltration in glomeruli as is shown in Figure 
17, wild-type mice have more macrophage and a significant difference was only observed at 
day 7 (Figure 20). Neutrophils as another important leukocyte subset, did not show any 
difference according to Ceacam1 genotype (Figure 21). Thus, CEACAM1 increases the renal 
leukocyte recruitment, namely of macrophages in GN. 
 
Figure 20  Macrophage infiltration in mice model in nephritis 
(A, B, D, E) Immunohistochemical Mac-2 staining and (C, F) Mac-2 staining quantitation in WT and Ceacam1-/- 
mice in GN.***p<0.001. 
 





Figure 21  Neutrophil infiltration in mice model in nephritis 
(A, B, D, E) Immunohistochemical Ly-6G staining and (C, F) Ly-6G staining quantitation in WT and Ceacam1-/- 
mice in GN. 
3.9 Ceacam1-/- enhances barrier function of human epithelial cells 
To further understand the association between CEACAM1 and GN, next ECIS 
experiment were performed using human epithelial cells and stimulating them with 
CEACAM1 activating antibody vs. PBS after damaging the cells with histones for 6h. Cells 
treated with the CEACAM1 antibody recovered slower than cells treated with PBS after 
histone damage (Figure 22), suggesting that CEACAM1 ligation prevents the recovery of 
cells after injury. 
 




                          
Figure 22  Effects of CEACAM1 in human epithelial cell culture model of barrier function 
Electric Cell-substrate Impedance Sensing experiments. Capacitance curves for histone stimulation and 
subsequent CEACAM1 antibody (CC1) treatment and control (PBS) for human epithelial cells. 
 
3.10 CEACAM1 effects on Anti-GBM disease are likely mediated by 
expression on endothelial cells 
3.10.1 CEACAM1 increases endothelial cell loss in anti-GBM mouse 
model 
Glomerular capillary loop endothelial cells are a vital part within the filtration barrier 
and can prevent the passage of large molecules, such as albumin. In this regard, it was 
known before that CEACAM1 can regulate glomerular capillary loop endothelial cells through 
VEGF and VEGF receptor [53], [103]. To test, whether CEACAM1 also influences endothelial 
cells in the Anti-GBM mouse model, endothelial cells were stained for CD31+ and the stained 
area was quantified. Indeed, while a decrease of CD31+ stained are was seen on day 1 
irrespective of Ceacam1 genotype, on day 7 there was a significantly larger area of CD31+ 
stained cells in Ceacam1-deficient mice compared to wild-type controls (Figure 23). 




Further evidence for a role of endothelial CEACAM1 was found performing electron 
microscopy (Figure 24): while all mice showed ultrastructural evidence of foot process 
effacement, no endothelial cell swelling or luminal thrombosis formation were found in 
Ceacam1-/- mice, whereas these findings were clearly present in wild-type controls after GN 
induction. 
Taken together, CEACAM1 induces endothelial cell swelling, luminal thrombosis and 
subsequent endothelial cell loss in the anti-GBM disease mouse model. 
 
Figure 23  CD31+ staining for endothelial cells after induced in Anti-GBM disease in mice  
(A, B, C and D) CD31+ staining for endothelial cells of WT day 1, Ceacam1-/- day 1, WT day 7 and Ceacam1-/- day 
7, respectively. (C and F) quantitation data of those section. **p<0.01. 
 





Figure 24  Image from electron microscopy of anti-GBM nephritis 
Luminal thrombosis formation (red arrow), endothelial cell swelling (green arrow) and foot process       















3.10.2 Ceacam1 deficiency attenuates glomerular endothelial cell 
death 
In addition to the aforementioned effects on endothelial cells, and also Ceacam1-/- 
mice showed less cell death (indicated by TUNEL+) in their glomeruli in GN at both day 1 and 
day 7 (Figure 25 A-F). To identify the specific cell type affected by cell death, kidney sections 
were co-stained with TUNEL (green) and CD31 (red), a co-staining identifying the dead cells 
as endothelial cells (Figure 25G). As there are many types of cell death, RIP3 phosphorylation 
was checked by western blot to identify necroptotic cell death. Figure 26 shows more RIP3 
phosphorylation in wild-type mice compared to Ceacam1-/- mice at day 1 but not day 7. In 
summary, CEACAM1 mediates endothelial cell death during GN at least partly by necroptosis 
induction. 





Figure 25  Endothelial cell death in nephritis 
Immunofluorescence staining and quantitation of endothelial cell death with TUNEL (TdT-mediated dUTP-
biotin nick end labeling) and CD31 (cluster of differentiation 31) staining in GN.  Section for TUNEL staining (A, B, 
D, E) and quantitation of section (C, F), section for TUNEL and CD31 co-staining (G). *p<0.05, ***p<0.001. 
 





Figure 26  Kidney tissue western blots of RIP3 in WT and Ceacam1-/- mice in nephritis 

















3.10.3 CEACAM1 expression is upregulated in endothelial cells after 
stimulation with lipopolysaccharide or histones  
As most of CEACAM1 is expressed by endothelial cells and there is an upregulation 
upon injury, cell culture experiments using murine endothelial cells were performed to 
identify possible triggers and mechanisms for upregulation. Endothelial cells were exposed 
to lipopolysaccharide (LPS) or histones for 6 h, supernatant free DNA concentration was 
measured and surviving cells were harvested for RNA isolation and Ceacam1 gene 
expression analysis. As expected, endothelial cell death was observed after stimulation with 
histones alone, and this was amplified by LPS pre-stimulation (Figure 27). The results show 
that after stimulated with LPS or histone for 6 h (Figure 28), Ceacam1 expression was 
significantly enhanced on endothelial cells compared with unstimulated cells. Taken 
together, while murine endothelial cells express low levels of CEACAM1 at baseline, there is 
a histone- and LPS-induced upregulation and this CEACAM1 upregulation is associated with 






































Figure 27  Endothelial cell death after stimulated with LPS and histone 
Endothelial cells are stimulated 6h with LPS fist and then stimulated with histone for another 6h.***p<0.001. 






Figure 28  Ceacam1 expression on endothelial cell after stimulated with LPS and histone 
Ceacam1 expression significant upregulate after exposed to LPS for 6 h at different concentration (0,5ug/ml 
and 1ug/ml), n= 3 (A). Ceacam1 expression increased after stimulated with histone (20ug/ml) n=3. *p<0.05, 
























3.10.4 Endothelial cell death leads to increased permeability in vitro 
To investigate whether the endothelial cell death and the subsequent GBM 
permeability observed in vivo can be observed also in vitro, transwell permeability assays 
were performed using murine endothelial cells after stimulation with LPS or histone. The 
results (Figure 29) shown that endothelial cell death can lead to permeability after damage 
by histone. This demonstrates that increased endothelial cell death leads to increased 
endothelial permeability. Thus, consistent with the in vivo data, CEACAM1 is upregulated 




Figure 29  Transwell permeability assay with bovine serum albumin 
Endothelial cells are stimulated for 6h (Left of the panel) or 24 h (Right of the panel) with LPS and histone. 










3.10.5 Endothelial cell death activates vascular endothelial growth 
factor and AKT signaling pathways leading to vascular 
permeability  
A powerful angiogenic factor that maintains the glomerular and peritubular capillary 
network is the VEGF. CEACAM1 signaling has been shown relative with the 
VEGFR2/AKT/eNOS-mediated vascular permeability pathway [65]. In fact, the mRNA level of 
Vegf and Vegf receptor were significant increase in wild-type mice at day 7 in GN (Figure 30). 
Consistent with this, an enhanced phosphorylation of AKT downstream signaling was also 
been seen in day 7 (Figure 31). Angiopoietins 1 and 2, ligands for receptor kinase Tie-2, are 
proposed to play vital but opposing function in vascular development with VEGF. Ang1, Ang2, 
Tie1 and Tie2 were in fact significantly increased in wild-type mice compared to Ceacam1-/- 
mice both at day1 and day 7 (Figure 32). In sum, the above findings suggest that CEACAM1 
signaling activates VEGF/VEGFR and AKT signaling pathways to promote vascular 
permeability upon GN. 
 
 
Figure 30  Gene expression of Vegf and Vegf receptor in GN 
Reverse transcriptase quantitative PCR (RT-qPCR) was used to quantitative for Vegf/Vegfr. VEGF: Vascular 
endothelial growth factor, VEGFR: Vascular endothelial growth factor receptor. *p<0.05, **p<0.01. 





Figure 31  Kidney tissue western blots in WT and Ceacam1-/- mice in GN 










Figure 32  Angiopoietins-1,2 and receptor kinase Tie-1,2 expression on kidney of nephritis 
Reverse transcriptase quantitative PCR (RT-qPCR) was used to quantitative for Ang1, Ang2, Tie-1 and Tie-2. 














3.10.6 Tight junction proteins decrease in endothelial cells after 
stimulation with histone and LPS  
The tight junction constitutes the barrier both to the molecules as well as passage of 
ions. When tight junction proteins are deceased, there is an increase in permeability of 
endothelial cells [104]. Tight junction proteins were also found to be downregulated after 
stimulation with histone and LPS (Figure 33). Taken together with the pervious data, 
CEACAM1 can increase the permeability of GBM by various mechanisms leading to 
albuminuria, for example through downregulation of tight junction proteins between 
endothelial cells. 





Figure 33  Tight junction proteins expression on endothelial cells 
Reverse transcriptase quantitative PCR (RT-qPCR) was used to quantitative for Occludin, Claudin-5, Claudin-12 
Claudin-15 and Zo-1. Zo-1: Zonula occludens-1, *p<0.05, **p<0.01. 






The goal of our work was to study the role of CEACAM1 in the pathogenesis of 
glomerulonephritis. I had hypothesized that CEACAM1 aggravates the death of endothelial 
cells and promote the development of nephritis, hence Ceacam1 knock-out mice should be 
protected during Anti-GBM nephritis. To explore the function of CEACAM1 in anti-GBM 
nephritis, I established an anti-GBM mouse model with Ceacam1-/- and wild-type mice. After 
induction of nephritis, Ceacam1-/- mice indeed showed various signs of an ameliorated 
phenotype: they had less albuminuria, decreased mRNA levels of injury markers as well as 
markers of inflammation, less podocyte loss and less leukocyte infiltration. These results are 
all consistent with my hypothesis. 
Based on the phenotype observed in human tissue samples and the Ceacam1- knockout 
mouse model of anti-glomerular basement membrane nephritis, the following conclusions 
arise in detail: 
1.  CEACAM1 is only expressed at low levels in normal mouse kidney and healthy human 
kidneys. Upon some, but not all injurious stimuli to the glomerular basement membrane, 
CEACAM1 is upregulated in the human kidney. CEACAM1 is also upregulated during the 
cause of anti-GBM disease in mice. 
2. In the mouse model, this upregulation of CEACAM1 aggravates the damage to the 
glomerular basement membrane by first injuring the capillary endothelial cells in the 
glomeruli, which in turn damages the basement membrane and leads to podocyte loss. 




3. CEACAM1 induced endothelial cell injury by regulating at least two pathways: a) the 
VEGF/AKT signaling pathway leading to downregulation of tight junction molecules, causing 
increased vascular permeability, and ultimately albuminuria. b) the RIPK1/RIPK3 pathway 
leading to increased endothelial cell death. 
4.1 CEACAM1 is mainly expressed on endothelial cells in the kidney 
 CEACAM1 is widely expressed in a many organs, tissues and cells, including the liver, 
colon, lymph nodes, testis, skeletal muscles, bone marrow and peripheral blood cells, (e.g. B 
and T cells, monocytes, neutrophils) and endothelial cells [42], [53], [64], [105]–[114]. There 
are tissue-specific differences: in the liver, CEACAM1 is expressed by immune cells and liver 
epithelial cells. CEACAM1 was first defined as a CEA-like product and a biliary glycoprotein 
(BGP) in human hepatic bile. Later, a particular correlation between BGP-I/soluble CEACAM1 
expression and obstructive liver disease has been recognized in patients [42], [64]. In fact, 
soluble CEACAM1 expression in rodents with liver disease is also strongly increased [115]. 
Additionally, in rats CEACAM1 is also expressed during the fetal period [116]. CEACAM1 can 
be detected in all biliary specimens, not only in malignant diseases [42], [117]. The 
expression of CEACAM1 major subtypes increased after birth, demonstrated that CEACAM1 
is a marker molecule in epithelial cell differentiation process.  
CEACAM1 is widely expressed in colitis and colon cancer. A recent study showed that 
exogenous CEACAM1 ameliorates the inflammatory response, improves epithelial barrier 
function, promotes recovery of epithelial cells, and effectively alleviates ulcerative colitis 
symptoms in the mouse model of colitis [109]. CEACAM1 expression defects are associated 
with early colorectal tumorigenesis [118], and compared with the control group, mice with 




Ceacam1 gene deletion are more likely to develop colon tumors after exposure to 
carcinogens [51]. These results shown that the absence of CEACAM1 is permissive to the 
development of colon tumors. 
CEACAM1 is expressed in a lot of immune cells, for example, B cells, neutrophils, 
macrophages, T cells as well as Natural Killer cells [68], [119]. Recently studies have 
indicated CEACAM1-L acts as an inhibitor of T cell activation by its ITIM motif based on a 
SHP-1-dependent manner [74], [120]–[122]. CEACAM1 has a function in B cell, although 
some results of the studies are contradictory [77], [78], [123], [124]. The antibody response 
of B cells to some viral antigens was shown to be CEACAM1-dependent [77], but the role of 
CEACAM1 in B cell neoplasms is debated. However, CEACAM1 seems to play a vital role in B 
cells as well as in T cells. 
Although CEACAM1 plays a very important role in many organs and tissues, there is 
little data on CEACAM1 in the kidney. According the KIT database of single-cell RNAseq data, 
CEACAM1 is mainly expressed on endothelial cells, with weaker expression on podocytes 
and proximal as well as distal tubular cells. To corroborate the findings on renal CEACAM1 
expression, I analyzed kidney tissues of both humans and mice by means of 
immunohistochemistry and confirmed the CEACAM1 expression to be confined mainly on 
endothelial cells with a very faint staining on podocytes. In addition, I could show that the 
relatively low CEACAM1 expression in normal kidneys was significantly upregulated in both 
human and murine anti-GBM disease. This is in agreement with another study that showed 
an up-regulation of CEACAM1 expression in renal tubules and/or glomerular cells during 
acute rejection of human kidney allografts [125]. Interestingly, while I observed an 




upregulation of CEACAM1 in human anti-GBM disease, I did not see such an effect in 
another form of human glomerular disease, namely diabetic nephropathy.  
4.2 CEACAM1 aggravates kidney injury in anti-GBM nephritis 
CEACAM1 can exert pro- and anti-inflammatory effects in different diseases. For 
example, CEACAM1 suppresses T-cell function after T-cell activation in colitis as a 
coinhibitory receptor. One study [126] found that CEACAM1 acts as a heterologous ligand 
for TIM-3 and mediates T cell suppression through the interaction of highly conserved 
membrane-distal N-terminal domains of each molecule, promoting TIM-3 maturation and 
cell surface expression. Additionally,  CEACAM1 is expressed on B-cell subsets [77], [127] and 
Khairnar et al. [77] demonstrated that the intrinsic signaling of CEACAM1 is critical for 
generating efficient B-cell responses, although CEACAM1 has a limited effect on B cell 
proliferation. In my study, I found CEACAM1 to be pro-inflammatory after the induction of 
anti-GBM nephritis: Ceacam1-deficient mice produce less inflammatory cytokines (CCL2, 
CCL5 and TNF-α) leading to less infiltration of macrophages. However, the details about how 
CEACMA1 acts as an inflammatory factor on B and T cells are not definitively clarified by my 
work. While I did not observe any difference in intrarenal CD3+ or CD19+ cells between 
Ceacam1-/- and Ceacam1+/+ mice, I did not assess B cell and T cell survival or proliferation in 
the nephritis mouse mode. However, my results show that CEACAM1 upregulation 
aggravates kidney injury in a totally different way, namely by damaging glomerular 
endothelial cells. Endothelial dysfunction, tubular injury and intrarenal inflammation are 
common pathophysiologic processes that occur in AKI. I establish here CEACAM1-mediated 
endothelial cell dysfunction as a driving force in the development of anti-GBM disease (see 




below). I also studied tubular injury markers such as NGAL, KIM-1, liver fatty acid-binding 
protein, as well as the two cell cycle arrest markers TIMP2 and IGFBP7 [128]–[135] and 
found a significant increase in Ceacam1-/- mice, but this tubular phenotype is rather 
secondary to the primary GBM injury. Conversely, Li et al. [88] demonstrated, that CEACAM1 
colocalizes with NLRC5 in proximal renal tubular cells. Interestingly, in their model of primary 
tubular injury by ischemia-reperfusion, CEACAM1 is downregulated in a NLRC5-dependent 
manner and the reversal of this downregulation is associated with an ameliorated 
phenotype mainly driven by anti-apoptotic functions of CEACAM1.  
Taken together, this suggests that CEACAM1 has differential, cell-type specific roles 
within the kidney. Hence, the net effect of CEACAM1 depends on the disease-context and 
which cell type or compartment (glomerular vs. tubular) is primarily affected.  
4.3 The VEGF/AKT pathway in the downstream signaling of 
CEACAM1 in anti-GBM nephritis 
From my previous results, I concluded that CEACAM1 aggravates the inflammation and 
injury in nephritis through damage the endothelial cell. This is exemplified by decreased 
glomerular crescent formation and less albuminuria in Ceacam1-/- mice.  As it was known 
that in endothelial cells CEACAM1 is involved in VEGF-dependent AKT signaling, AKT and 
VEGF/VEGFR1/2 levels were detected by WB and RT-qPCR. The observed upregulation 
during the course of anti-GBM nephritis is consistent with previous research results, showing 
that VEGF plays a very crucial role in endothelial dysfunction [136]–[138]. Complex local 
autocrine and paracrine pathways (podocytes and glomerular endothelial cells) are crucial to 
the filtration barrier homeostasis, where podocytes secrete various factors that directly 




affect the glomerular endothelium [139], [140]. Several studies have shown that VEGF has 
an important function in the maintenance of the glomerular capillary as well as for 
endothelial permeability [141]–[143]. The imbalance between VEGF and VEGF receptor 1/2 
has been mentioned in a variety of diseases, such as kidney disease, in which regulation of 
VEGF signaling is related to impaired endothelial barrier, endothelial dysfunction, as well as 
increased proteinuria [144]–[147]. While the contribution to chronic kidney disease 
progression is unknown, it is saved to say that VEGF/VEGFR takes part in the process of 
endothelial dysfunction in nephritis. More recently, studies have shown that AKT signaling 
also participates in VEGF production [148], [149]. So how about the relationship between 
CEACAM1 and AKT/VEGF pathway in anti-GBM disease? My results show that Ceacam1-/- 
mice have a largely blunted VEGF/VEGFR upregulation upon glomerular injury and hence 
less AKT phosphorylation. The effect of this should be less vascular permeability, indeed 
found by the reduced proteinuria Ceacam1-/- mice compared wild-type mice. In 2010, one 
study [65] found that CEACAM1 is essential to maintain vascular integrity in ischemic 
neovascularization, but in this study the basal vascular permeability of Ceacam1-/- mice was 
significantly increased, which was associated with increased activation of AKT and 
endothelial nitric oxide synthase in mice lung endothelial cells. While this is in contrast with 
my findings, in the same study the deletion of Ceacam1 in lung endothelial cells inhibited 
VEGF mediated nitric oxide production, consistent with the downstream VEGF signaling 
defects in my Ceacam1 -/- mice after anti-GBM disease induction. While it is difficult to 
explain these partly contrasting phenotypes, the function of CEACAM1 might differ between 
lung and kidney endothelial cells and their response to injurious stimuli. 




Taken together, CEACAM1 aggravates anti-GBM nephritis through activating the 
VEGF/AKT pathway in glomerular endothelial cells. 
4.4 CEACAM1-mediated endothelial cell death in anti-GBM 
nephritis 
Cell death is a part of the normal process of growth as well as maturation, and it is a 
key and positive process for maintaining tissue homeostasis and eliminating potentially 
harmful cells in multicellular organisms [150]–[154]. Regulated cell death is already known 
to be take part in the pathogenesis of many different acute kidney diseases[155]. In the past 
two decades, mainly tubular cell death has been found in preclinical models of AKI and in 
patients [119], [121], [132], [156]. Glomerular mesangial cells and endothelial cells are the 
three most important cell types in the glomerulus, and cell death has mostly been studied in 
endothelial cells [157]–[160]. Glomerular endothelial cell dysfunction and death are involved 
in the pathogenesis of nephrotic syndrome in general [132]. Necroptosis is a kind of gene-
regulated necrotic cell death that has become an vital pathogenic pathway for many 
diseases of human [161]–[163]. RIPK1 and RIPK3 (receptor-interacting protein kinases 1 and 
3) and MLKL (mixed-lineage kinase domain-like pseudo kinase) form a regulatory necrosome 
complex together induce the necroptosis pathway. MLKL phosphorylation mediated by 
RIPK3 induces necroptosis. Consistent with previous studies, I found endothelial cell death 
during the course of anti-GBM disease, shown by TUNEL / CD31 double-positive cells in the 
glomerulus. Interestingly, a difference in TUNEL staining observed between Ceacam1-/- and 
Ceacam1+/+ mice was found, with lower numbers of TUNEL+ cells in Ceacam1-/- mice. As 
different routines of regulated cell death can occur in kidney endothelial cells, and TUNEL 




staining is not, as previously thought, apoptosis-specific, I investigated this phenotype 
further. I found increasing levels of phosphorylated RIPK3 during the cause of anti-GBM 
disease, while phosphorylated RIPK3 was reduced in the kidneys of Ceacam1-/- mice 
compared to Ceacam1+/+ mice on day1. This suggests two things: i) glomerular endothelial 
cell necroptosis is involved during the development of anti-GBM nephritis, as already found 
by others[164].  ii) CEACAM1 regulates this process in a pro-necroptotic fashion. 
Recently, one study found RIPK3 to be strongly expressed in human chronic kidney 
disease (CKD) [165]. Another study found that up-regulation and interaction of RIPK3 and 
MLKL induce necroptosis of renal proximal tubule cells under renal ischemia-reperfusion 
injury (IRI) conditions [166]. Necrosis can trigger inflammation, which enhances the positive 
feedback loop of necrosis, which in turn triggers more inflammation, called necrotic 
inflammation. However, the mechanism of necrosis-induced inflammation caused by renal 
tubular necroptosis in the progression of AKI to CKD remains unclear. They also found that 
up-regulation and interaction of RIPK3 and MLKL under IRI conditions induce renal proximal 
tubule cell necroptosis and promote activation of NLRP3 inflammatory bodies [166]. Most of 
them found is that necroptosis happens in kidney tubular cells, not endothelial cells. Except 
one study reveals that anti-neutrophil cytoplasmic antibody (ANCA) stimulated neutrophils 
induced endothelial cell damage via RIPK1/3 and MLKL-dependent necroptosis. This further 
proves that my findings are correct. 
 




4.5 Limitations of this study 
To study the effect of CEACAM1 on Anti-GBM nephritis, I used Ceacam1 knockout mice 
and the mouse model of anti-GBM disease. While this allowed me for detailed analysis and 
the assessment of causation (rather than association), the research presented here has 
several important limitations: First and foremost, my study is based on conclusions of mouse 
experiments. The results presented here are therefore not necessarily representative of 
human renal biology and pathogenesis. Although most scientists use mice for experimental 
research [167], [168], there are big differences between the human body environment and 
the mouse environment. It takes a certain amount of time to transform from scientific 
research results to clinical applications. It is however promising, that at least the 
upregulation of CEACAM1, that is observed in the mouse model, is mirrored in the 
corresponding human disease. 
Second, the way I induced Anti-GBM nephritis leads to a heterologous nephritis. While 
this methods has previously been described [94] and is widely applied, it has certain 
shortcomings. The serum is not identical between different product batches, which can 
affect the reproducibility of mouse model.  I had to use 200 µl serum to induce 
glomerulonephritis, while previous researchers from our group [94] only used a 100 µl 
serum to successfully induce anti-GBM disease. An alternative to the heterologous model is 
the use of the autologous model, where generally lower doses of serum are necessary, as 
the host is actively being immunized.  
Third, many additional experiments could be envisioned to further characterize the 
phenotype of Ceacam1-/- mice in more detail: while I analyzed bulk RNA isolated from whole 




kidneys, this analysis could be strengthened by microdissection the kidneys and separating 
the glomerular and the tubular compartment, or ideally by single-cell RNA sequencing. This 
would allow for a detailed cell-type specific analysis of downstream effects of the Ceacam1 
knock-effect. Also, the use of bone-marrow chimeras or ideally conditional, i.e. cell-type 
specific knock-out mice (e.g. via crossing Ceacam1flox/flox mice with endothelial cell promotor-
specific cre-expressing mice) would be needed to definitively proof the suggested 
endothelial cell specific effects of CEACAM1.  
Fourth, in the necroptosis experiments I did not check the MLKL phosphorylation levels 

























Glomerulonephritis is characterized by increasing membrane permeability due to 
impaired glomerular basement membrane eventually leads to hyperplasia of the basement 
membrane to form a crescent. the antibody will bind to the membrane then activate the 
immune system. previous study has shown that endothelial cell death plays a key role in 
nephritis, other studies already demonstrated that CEACAM1 regulates the endothelial 
barrier function in vasculogenesis and angiogenesis. But there is no published paper reveal 
the relationship between the function of CEACAM1 and glomerulonephritis.  In this thesis, I 
investigated whether CEACAM1 produces similar effects during glomerulonephritis. 
CEACAM1 knockout mice were used during this experiment, and glomerulonephritis was 
induced by injection of 200 ul sheep anti-GBM serum.  
To observe the function of CEACAM1 in nephritis, the phenotype between wild-type 
mice and CEACAM1-/- mice were compared. Mice treated with Anti-GBM serum showed 
increased BUN and proteinuria levels, this because the lost endothelial cells and podocytes 
of GBM, increased glomerular crescent formation and basement membrane permeability. In 
my results, CEACAM1 expression is significant upregulate after induce nephritis. CEACAM1 
deficient mice shown less kidney injury and infiltration of inflammatory factors, reduced 
endothelial cell death, decreased AKT phosphorylation and VEGF/VEGFR RNA levels. This is 
consistent with my hypothesis that CEACAM1 plays a pathogenic role in the heterologous 
anti GBM disease mouse model of crescentic nephritis.  
In summary, CEACAM1 aggravates nephritis through the endothelial cell by activating 
AKT/VEGF pathway in heterologous glomerulonephritis. 






In der Pathogenese der Glomerulonephritis kommt es durch entzündungsbedingte 
Schädigung der glomerulären Basalmembran zur Permeabilitätserhöhung, die zu Proteinurie, 
Aktivierung der Parietalzellen („Halbmondbildung“), Vernarbung und letztlich renalem 
Funktionsverlust führt. In diesem Prozess spielen Wachstumsfakturen (z.B. VEGF) und Zell-
Zell-Verbindungen (tight junctions) ebenso eine Rolle wie die Induktion regulierten Zelltods. 
CEACAM1 ist ein wichtiger Regulator der Endothelbarrierefunktion, die Rolle von CEACAM1 
in der Pathogense der Glomerulonephritis war bislang aber unbekannt.  
Um die Funktion von CEACAM1 in der Pathogenese der Glomerulonephritis zu 
beobachten, wurde der Phänotyp zwischen Ceacam1+/+ und Ceacam1-/- Mäusen nach der 
Induktion einer Glomerulonephritis verglichen. Während die CEACAM1 Expression während 
der Pathogenese der Glomerulonephritis signifikant ansteigt, zeigen Ceacam1-/- Mäuse einen 
deutlich milderen Phänotyp: sie haben niedigere Serumretentionsparamenter, weniger 
Albuminurie, weniger intrarenale Entzündung und weniger endothelialen Zelltod. Dieser 
Phänotyp ist mit einer deutlich geringeren Aktivierung des VEGF/AKT Signalwegs in vivo 
assoziiert. Zusammenfassend verschlimmert CEACAM1 den Verlauf der Glomerulonephritis 








7 List of abbreviations 
__________________________________________________ 
CEACAM1           Carcinoembryonic antigen-related cell adhesion molecule 1  
Anti-GBM            Anti–glomerular basement membrane 
GN                 Glomerulonephritis 
AKI     Acute kidney injury 
CEACAM1-4L Namely Carcinoembryonic antigen-related cell adhesion molecule 1 1-4 
longer  
CEACAM1-4S Namely Carcinoembryonic antigen-related cell adhesion molecule 1 1-4 
short 
VEGF                 Vascular endothelial growth factor 
VEGFR1    Vascular endothelial growth factor receptor1 
VEGFR2    Vascular endothelial growth factor receptor2  
eNOS     Endothelial nitric oxide synthase 
cDNA     Complementary desoxyribonucleic acid 
ITIMs     Immunoreceptor tyrosine receptor inhibition motifs 
COL1A1    Collagen type I alpha 1 chain 
TIM-3     T-cell immunoglobulin and mucin-domain containing-3 
NK     Natural killer 
AKT     Protein kinase B 
DMEM     Dulbecco's modified Eagle media 
PI3K     Phosphoinositide 3-kinases 
ECIS     Epithelial barrier testing via electric cell–substrate impedance sensing  




RNA     Ribonucleic acid 
BUN      Blood urea nitrogen 
PAS     Periodic acid–Schiff 
SD     Standard deviation 
GBM     Glomerular basement membrane 
GFR     Glomerular filtration rate 
PBS     Phosphate-buffered saline 
CD31     Cluster of differentiation 31  
TUNEL     Terminal deoxynucleotidyl transferase dUTP nick end labeling 
Ctrl     Control 
NGAL     Neutrophil gelatinase-associated lipocalin  
KIM-1     Kidney Injury Molecule-1 
TIMP2     Tissue inhibitor of metalloproteinases 2 
IGFBP7                Insulin-like growth factor-binding protein 7 
CCL2     Chemokine (C-C motif) ligand 2 
TNF-alpha    Tumour Necrosis Factor alpha  
CCL5     Chemokine (C-C motif) ligand 5 
CXCL1                 Chemokine (C-X-C motif) ligand 1 
CXCL2                 Chemokine (C-X-C motif) ligand 2 
LPS     Lipopolysaccharides 
qPCR     quantitative polymerase chain reaction 
RT     Reverse transcription 
G                         Germany 
C                          China 
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